Here's What Analysts Are Forecasting For Alembic Pharmaceuticals Limited (NSE:APLLTD) After Its Annual Results

As you might know, Alembic Pharmaceuticals Limited (NSE:APLLTD) just kicked off its latest yearly results with some very strong numbers. The company beat expectations with revenues of ₹67b arriving 2.5% ahead of forecasts. Statutory earnings per share (EPS) were ₹29.68, 3.8% ahead of estimates. Following the result, the analysts have updated their earnings model, and it would be good to know whether they think there's been a strong change in the company's prospects, or if it's business as usual. We've gathered the most recent statutory forecasts to see whether the analysts have changed their earnings models, following these results.

We've discovered 1 warning sign about Alembic Pharmaceuticals. View them for free.

Following the latest results, Alembic Pharmaceuticals' eleven analysts are now forecasting revenues of ₹74.1b in 2026. This would be a meaningful 10% improvement in revenue compared to the last 12 months. Statutory earnings per share are predicted to soar 23% to ₹36.43. In the lead-up to this report, the analysts had been modelling revenues of ₹73.4b and earnings per share (EPS) of ₹39.21 in 2026. The analysts seem to have become a little more negative on the business after the latest results, given the minor downgrade to their earnings per share numbers for next year.

See our latest analysis for Alembic Pharmaceuticals

The consensus price target held steady at ₹1,015, with the analysts seemingly voting that their lower forecast earnings are not expected to lead to a lower stock price in the foreseeable future. That's not the only conclusion we can draw from this data however, as some investors also like to consider the spread in estimates when evaluating analyst price targets. The most optimistic Alembic Pharmaceuticals analyst has a price target of ₹1,345 per share, while the most pessimistic values it at ₹885. As you can see, analysts are not all in agreement on the stock's future, but the range of estimates is still reasonably narrow, which could suggest that the outcome is not totally unpredictable.

One way to get more context on these forecasts is to look at how they compare to both past performance, and how other companies in the same industry are performing. The analysts are definitely expecting Alembic Pharmaceuticals' growth to accelerate, with the forecast 10% annualised growth to the end of 2026 ranking favourably alongside historical growth of 6.0% per annum over the past five years. Compare this with other companies in the same industry, which are forecast to grow their revenue 10% annually. Alembic Pharmaceuticals is expected to grow at about the same rate as its industry, so it's not clear that we can draw any conclusions from its growth relative to competitors.

The Bottom Line

The most important thing to take away is that the analysts downgraded their earnings per share estimates, showing that there has been a clear decline in sentiment following these results. They also reconfirmed their revenue estimates, with the company predicted to grow at about the same rate as the wider industry. The consensus price target held steady at ₹1,015, with the latest estimates not enough to have an impact on their price targets.

Keeping that in mind, we still think that the longer term trajectory of the business is much more important for investors to consider. We have forecasts for Alembic Pharmaceuticals going out to 2028, and you can see them free on our platform here.

It is also worth noting that we have found 1 warning sign for Alembic Pharmaceuticals that you need to take into consideration.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.